Quantifying and Adjusting for Confounding From Health-Seeking Behavior and Health Care Access in Observational Research.
COVID-19
confounding from health-seeking behavior and health care access
influenza
vaccine effectiveness
vaccines
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
received:
10
07
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
Health-seeking behavior and health care access (HSB/HCA) are recognized confounders in many observational studies but are not directly measurable in electronic health records. We used proxy markers of HSB/HCA to quantify and adjust for confounding in observational studies of influenza and COVID-19 vaccine effectiveness (VE). This cohort study used primary care data prelinked to secondary care and death data in England. We included individuals aged ≥66 years on 1 September 2019 and assessed influenza VE in the 2019-2020 season and early COVID-19 VE (December 2020-March 2021). VE was estimated with sequential adjustment for demographics, comorbidities, and 14 markers of HSB/HCA. Influenza vaccination in the 2019-2020 season was also considered a negative control exposure against COVID-19 before COVID-19 vaccine rollout. We included 1 991 284, 1 796 667, and 1 946 943 individuals in the influenza, COVID-19, and negative control exposure populations, respectively. Markers of HSB/HCA were positively correlated with influenza and COVID-19 vaccine uptake. For influenza, adjusting for HSB/HCA markers in addition to demographics and comorbidities increased VE against influenza-like illness from -1.5% (95% CI, -3.2% to .1%) to 7.1% (95% CI, 5.4%-8.7%) with a less apparent trend for more severe outcomes. For COVID-19, adjusting for HSB/HCA markers did not change VE estimates against infection or severe disease (eg, 2 doses of BNT162b2 against infection: 82.8% [95% CI, 78.4%-86.3%] to 83.1% [95% CI, 78.7%-86.5%]). Adjusting for HSB/HCA markers removed bias in the negative control exposure analysis (-7.5% [95% CI, -10.6% to -4.5%] vs -2.1% [95% CI, -6.0% to 1.7%] before vs after adjusting for HSB/HCA markers). Markers of HSB/HCA can be used to quantify and account for confounding in observational vaccine studies.
Sections du résumé
Background
UNASSIGNED
Health-seeking behavior and health care access (HSB/HCA) are recognized confounders in many observational studies but are not directly measurable in electronic health records. We used proxy markers of HSB/HCA to quantify and adjust for confounding in observational studies of influenza and COVID-19 vaccine effectiveness (VE).
Methods
UNASSIGNED
This cohort study used primary care data prelinked to secondary care and death data in England. We included individuals aged ≥66 years on 1 September 2019 and assessed influenza VE in the 2019-2020 season and early COVID-19 VE (December 2020-March 2021). VE was estimated with sequential adjustment for demographics, comorbidities, and 14 markers of HSB/HCA. Influenza vaccination in the 2019-2020 season was also considered a negative control exposure against COVID-19 before COVID-19 vaccine rollout.
Results
UNASSIGNED
We included 1 991 284, 1 796 667, and 1 946 943 individuals in the influenza, COVID-19, and negative control exposure populations, respectively. Markers of HSB/HCA were positively correlated with influenza and COVID-19 vaccine uptake. For influenza, adjusting for HSB/HCA markers in addition to demographics and comorbidities increased VE against influenza-like illness from -1.5% (95% CI, -3.2% to .1%) to 7.1% (95% CI, 5.4%-8.7%) with a less apparent trend for more severe outcomes. For COVID-19, adjusting for HSB/HCA markers did not change VE estimates against infection or severe disease (eg, 2 doses of BNT162b2 against infection: 82.8% [95% CI, 78.4%-86.3%] to 83.1% [95% CI, 78.7%-86.5%]). Adjusting for HSB/HCA markers removed bias in the negative control exposure analysis (-7.5% [95% CI, -10.6% to -4.5%] vs -2.1% [95% CI, -6.0% to 1.7%] before vs after adjusting for HSB/HCA markers).
Conclusions
UNASSIGNED
Markers of HSB/HCA can be used to quantify and account for confounding in observational vaccine studies.
Identifiants
pubmed: 39474443
doi: 10.1093/ofid/ofae598
pii: ofae598
pmc: PMC11518854
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofae598Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflict of interests: S. G. is a part-time salaried employee of Evidera, which is a business unit of Pharmaceutical Product Development, part of Thermo Fisher Scientific. All other authors report no potential conflicts.
Références
J Public Health (Oxf). 2014 Dec;36(4):684-92
pubmed: 24323951
Open Heart. 2017 Mar 9;4(1):e000417
pubmed: 28761670
Lancet. 2005 Oct 1;366(9492):1165-74
pubmed: 16198765
Pharmacoepidemiol Drug Saf. 2019 Jul;28(7):993-1001
pubmed: 31168897
Stud Health Technol Inform. 2018;247:161-165
pubmed: 29677943
JAMA Netw Open. 2022 Sep 1;5(9):e2233730
pubmed: 36169955
Lancet Digit Health. 2021 Dec;3(12):e773-e783
pubmed: 34823706
BMJ Open. 2024 Sep 26;14(9):e081781
pubmed: 39327051
Indian J Community Med. 2023 Jan-Feb;48(1):161-166
pubmed: 37082383
Int J Epidemiol. 2017 Aug 1;46(4):1093-1093i
pubmed: 28338941
PLoS One. 2017 Jan 26;12(1):e0170550
pubmed: 28125629
PLoS One. 2018 Nov 15;13(11):e0207183
pubmed: 30439975
Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1500-1506
pubmed: 28840621
JAMA Netw Open. 2018 Jul 6;1(3):e180826
pubmed: 30646034
BMJ. 2022 Jul 20;378:e071249
pubmed: 35858698
J Clin Epidemiol. 2009 Jul;62(7):687-94
pubmed: 19124221
Epidemiology. 2010 May;21(3):383-8
pubmed: 20335814
BMJ. 2022 Jul 20;378:e068946
pubmed: 35858680
Arch Environ Health. 1966 Apr;12(4):531-41
pubmed: 5324641
Clin Infect Dis. 2021 Dec 6;73(11):e4251-e4259
pubmed: 33211809
BMJ. 2017 Oct 16;359:j4587
pubmed: 29038130
Pharmacoepidemiol Drug Saf. 2007 Jun;16(6):627-40
pubmed: 17286319
Vaccines (Basel). 2021 May 20;9(5):
pubmed: 34065294
N Engl J Med. 2007 Oct 4;357(14):1373-81
pubmed: 17914038
J Infect Dis. 2020 Jun 29;222(2):278-287
pubmed: 32100009
BMC Health Serv Res. 2023 May 16;23(1):490
pubmed: 37189156
J Infect. 2022 May;84(5):675-683
pubmed: 34990709
Int J Epidemiol. 2019 Dec 1;48(6):1740-1740g
pubmed: 30859197
Ann Intern Med. 2023 May;176(5):685-693
pubmed: 37126810
Emerg Med J. 2016 Mar;33(3):200-7
pubmed: 26396232